Nordicus Partners Reports $1.21 Million Net Loss and No Revenue for Quarter Ending June 30, 2025

Nordicus Partners Corporation reported its financial results for the three months ending June 30, 2025, revealing a net loss of $1.21 million, compared to a loss of $258,169 in the same period last year. The company did not generate any revenue during this quarter, maintaining a trend from the previous year. Operating expenses surged to $831,886, a significant increase from $258,169 in the prior year, primarily driven by higher officer compensation, professional fees, and research and development costs associated with its biotechnology subsidiaries, Orocidin A/S and Bio-Convert A/S.

The company's total assets increased to $76.12 million as of June 30, 2025, up from $70.25 million at the end of the previous fiscal quarter. This growth was largely attributed to an increase in in-process research and development assets, which rose to $46.57 million from $42.71 million. Goodwill also saw an increase, reaching $27.79 million, reflecting the company's ongoing investments in its biotechnology ventures. The total liabilities stood at $11.86 million, up from $10.38 million, primarily due to an increase in accounts payable and accrued expenses.

Strategically, Nordicus has focused on expanding its portfolio in the life sciences sector. The company completed the acquisition of Orocidin A/S and Bio-Convert A/S, both preclinical-stage biotechnology firms, which are developing innovative treatments for periodontitis and oral leukoplakia, respectively. The company’s operational developments include successful toxicology studies for Orocidin's lead product, QR-01, and positive feedback from the Danish Medicines Agency regarding Bio-Convert's QR-02 treatment. These advancements are expected to enhance the companies' market positions and drive future growth.

As of June 30, 2025, Nordicus reported a cash balance of $8,418, a decrease from $19,914 at the end of the previous quarter. The company utilized $425,698 in operating activities during the quarter, compared to $217,549 in the same period last year. The increase in cash used is attributed to higher operating expenses, although the company raised $409,970 through the issuance of common stock during the quarter. The management indicated that the company’s current cash reserves are insufficient to meet its operational needs for the next twelve months, raising concerns about its ability to continue as a going concern.

Looking ahead, Nordicus aims to leverage its acquisitions to generate profitable operations and secure additional financing. The company plans to finance its operating costs through existing cash and potential private placements of common stock. Management remains optimistic about the future, citing the potential of its biotechnology portfolio to address unmet medical needs in the market. However, the company acknowledges the inherent risks associated with its operations and the need for continued investment to achieve its strategic objectives.